Abstract
Background: β-Blockers are a cornerstone in the treatment of systolic heart failure treatment, but not all β-blockers are effective or in this setting. Objective: To define the role of bisoprolol, a highly selective β1-antagonist in congestive heart failure due to systolic dysfunction. Methods: Using the keywords ‘bisoprolol’ and ‘heart failure’ PubMed and BIOSIS databases were searched for information regarding pharmacology and relevant randomised clinical trials. Supplementary publications were acquired by scrutinising reference lists of relevant papers. Additional information was obtained from the FDA website. Conclusion: Bisoprolol is an effective and well-tolerated first-line β-blocker for patients with systolic heart failure. The knowledge is primarily based on study patients with moderate-to-severe heart failure from the three CIBIS trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
